This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Elise A. Olsen, MD; Susan C. Carson, MD; Elizabeth A. Turney

Arch Dermatol. 1992;128(11):1467-1473.

Abstract
• Background and Design.—
Thirty-two patients with mild to extensive alopecia areata, including 16 patients with alopecia totalis or universalis, entered a randomized, controlled trial of a 6-week taper of prednisone followed by either 2% topical minoxidil or vehicle applied three times daily for an additional 14 weeks. The results of this study were compared with an open trial of 48 patients with alopecia areata treated with a similar taper of prednisone with concomitant 2% topical minoxidil applied twice daily. Only terminal hair growth was considered and was quantitated as 1% to 24%, 25% to 49%, 50% to 74%, and 75% to 100%: only those with more than 25% terminal hair regrowth were considered to have had an objective response.

Results.—
At the end of 6 weeks of prednisone, 47% (15/32) of patients had more than 25% regrowth, including nine of 20 patients who had had at least 75% hair loss at baseline. Side effects of prednisone were primarily weight gain and mood changes/emotional lability. At 3 months, six of seven minoxidil-treated patients vs one of six vehicle-treated patients who had an objective response to prednisone maintained or augmented this hair growth: at the 20-week visit, these numbers were three of seven and zero of four patients, respectively. In the open trial, objective hair growth with prednisone was 30%, related to the extent of hair loss at baseline, and this growth persisted in more than 50% of patients at 6 months with the use of 2% topical minoxidil.

Conclusions.—
A 6-week taper of prednisone offers potential for more than 25% regrowth in 30% to 47% of patients with alopecia areata with predictable and transient side effects. Two percent topical minoxidil three times daily appears to help limit poststeroid hair loss.

(Arch Dermatol. 1992;128:1467-1473)

Author Affiliations
From the Division of Dermatology, Department of Medicine, Duke University Medical Center, Durham, NC (Drs Olsen and Carson); and the Department of Biostatistics, University of North Carolina, Chapel Hill (Ms Turney).

Footnotes
Accepted for publication January 30, 1992.

Reprint requests to Box 3294, Duke University Medical Center, Durham, NC 27710 (Dr Olsen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Da Silva et al.
Ann Rheum Dis 2006;65:285-293.
ABSTRACT | FULL TEXT  

Alefacept for Alopecia Areata
Heffernan et al.
Arch Dermatol 2005;141:1513-1516.
FULL TEXT  

Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus
Chau and Mok
Neurology 2003;61:104-107.
ABSTRACT | FULL TEXT  

Treatment of Hair Loss
Price
NEJM 1999;341:964-973.
FULL TEXT